{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:15:23Z","timestamp":1793650523104,"version":"4.5.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>JAK-inhibitors (JAK-i) represent an effective treatment in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). Oral glucocorticoids (OGC) are commonly used in combination with JAK-i to reach therapeutic target. We aimed to assess, in a real-life setting, the reduction of OGC dose during JAK-i treatment in active RA and PsA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively enrolled 103 patients (88 RA, 15 PsA) treated with JAK-i: 24% bio-na\u00efve (b-na\u00efve), 76% bDMARD-insufficient responders (bDMARD-IR) and 40% difficult to treat (D2T), defined as failure of \u22652 bDMARDs with different mechanism of action. Disease activity (DAS28 and DAPSA, VAS-pain, GH) and OGC dose was collected at baseline and after 3, 6 and 12 months (T3, T6, T12) of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In all the cohort and in b-na\u00efve patients we reported a reduction of OGC dose at all time-points; bDMARD-IR patients were able to reduce OGC dose at T3 and T12; D2T ones only at T3. We reported an improvement of disease activity and withdrawal of OGC as early as three months of therapy, at all time-points, regardless of line of bDMARD treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Chronic OGC may cause detrimental bone, metabolic, cardiovascular side effects and infections; therefore JAK-i steroid-sparing effect may be beneficial for patients in long-term treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1376476","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:17:46Z","timestamp":1712881066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["The steroid-sparing effect of JAK inhibitors across multiple patient populations"],"prefix":"10.3389","volume":"15","author":[{"given":"Paola","family":"Conigliaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Minerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vendola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Fiannacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Triggianese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kroegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to convetional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001749","article-title":"The risk of infections associated with JAK inhibitors in rheumatoid arthritis: A systematic review and network meta-analysis","volume":"28","author":"Alves","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2039630","article-title":"Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events","volume":"18","author":"Atzeni","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B12","unstructured":"EMA recommends measures to minimize risk of serious side effects with Janus kinase inhibitors"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"5","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes279","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51","author":"Kay","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"B18","article-title":"Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA)","volume":"33","author":"Smolen","year":"2015","journal-title":"A Brief Review Clin Exp Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.42347","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"75","author":"Studenic","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2626-y","article-title":"Ferreyra Garrott L.Remission criteria and activity indices in psoriatic arthritis","volume":"33","author":"Acosta Felquer","year":"2014","journal-title":"Clin Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MRR.0b013e3282fc0f93","article-title":"Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain","volume":"31","author":"Boonstra","year":"2008","journal-title":"Int J Rehabil Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201142","article-title":"Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06836-w","article-title":"ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy","volume":"43","author":"D'Alessandro","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"21907","DOI":"10.1038\/s41598-020-78925-8","article-title":"Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry","volume":"10","author":"Takahashi","year":"2020","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211014019","article-title":"Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience","volume":"13","author":"Tesei","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00810-7","article-title":"Sex- and gender-related differences in psoriatic arthritis","volume":"18","author":"Tarannum","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00535-3","article-title":"Psoriatic arthritis in males and females: differences and similarities","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B29","article-title":"Factors predicting 2 years of remission and low disease activity in rheumatoid arthritis patients treated with TNF-inhibitors","volume":"19","author":"Conigliaro","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2106970","article-title":"Epidemiology of rheumatoid arthritis: genetic and environmental influences","volume":"18","author":"Venetsanopoulou","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010055","article-title":"Tailoring rheumatoid arthritis treatment through a sex and gender lens","volume":"13","author":"Carmona","year":"2024","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3769-4","article-title":"A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors","volume":"36","author":"Chimenti","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B33","article-title":"The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years","volume":"31","author":"Tengstrand","year":"2004","journal-title":"J Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/ar2591","article-title":"Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study","volume":"11","author":"Sokka","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15537","DOI":"10.1038\/s41598-023-42371-z","article-title":"Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib","volume":"13","author":"Spinelli","year":"2023","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/pudtpo","article-title":"Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study","volume":"39","author":"Guidelli","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S414739","article-title":"Potential mechanism of fatigue induction and its management by JAK inhibitors in inflammatory rheumatic diseases","volume":"16","author":"Felis-Giemza","year":"2023","journal-title":"J Inflammation Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-00995-z","article-title":"Early response to JAK inhibitors on central sensitization and pain catastrophizing in patients with active rheumatoid arthritis","volume":"30","author":"Salaffi","year":"2022","journal-title":"Inflammopharmacology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab654","article-title":"The impact of education inequality on rheumatoid arthritis risk is mediated by smoking and body mass index: Mendelian randomization study","volume":"61","author":"Zhao","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa179","article-title":"The impact of smoking on prevalence of psoriasis and psoriatic arthritis","volume":"59","author":"Gazel","year":"2020","journal-title":"Rheumatol (Oxford)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1376476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:17:49Z","timestamp":1712881069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1376476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2024.1376476"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1376476","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"article-number":"1376476"}}